Sören Creutzburg
@Soeren_Berlin
Followers
1K
Following
8K
Media
194
Statuses
2K
I help brands & creators turn attention into revenue. Entrepreneur | Builder | Strategist | Analyst - Founder @ Anyjoi | Blitzhype
Berlin, Germany
Joined May 2019
$XBI $SGMO The edge come with an informed, differentiated thesis the market is missing
1
3
25
$SGMO Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy!!!!! Strong Buy!
Traditional painkillers (especially non-opioid, novel targets) often fail because the underlying mechanism is unclear or insufficiently validated (e.g., channel blockers, GPCR antagonists without clear evidence that they actually influence pain). With $SGMOs Nav1.7, on the other
5
3
44
$SGMO Seeing some speculation, so let me clarify a few things: 1. I have very little time to be online on X lately. And yes — I’m also annoyed by the anti-communication approach from management and the fact that they’re not using support where it’s needed. I’m still fully here
21
3
47
🚨FDA just published in @NEJM a new "plausible mechanism pathway" for personalised therapies! Actually detailed by Makary & Prasad...and inspired by Baby KJ's CRISPR success. Companies will be allowed to leverage 'platform data' (e.g, safety and scientific info from prior
7
16
59
We’re getting very close to my $NTLA average buy-in and I feel with @GeneInvesting. While the recent patient death is unfortunate, the individual was in their 80s — these things sadly happen in late-stage studies. The overall risk/reward for patients remains highly favorable.
@GeneInvesting Oh dear @GeneInvesting — even though you took a piss on my beloved Sangamo every chance you got, let me tell you I’m with you on $NTLA . I’ll be allocating 15–25% across portfolios as soon as we hit €7-7.50 again. All just temporary spoon-feeding — same story as $SRPT. People
4
0
3
Arrived in the accommodation and run through the update. I quite like @Franca_ole summary for $SGMO: nothing changed (in terms of cash) — everything else progressed positively. More cash than expected. No further atm or other fundraising and everything aligning for the Fabry
Let's pause, take a deep breath, and think: what has changed today? $SGMO has announced its quarterly figures and confirmed that the FDA has accepted kidney function and the eGFR slope marker for accelerated approval of ST-920 for the treatment of Fabry disease! In the current
10
2
32
$SGMO peoples retarded reaction in no news is the only thing annoying to me so far.
13
1
23
$SGMO - this nothingburger is the second best thing we could have hoped for. No cash raise means deal progressing as planned.
18
2
42
$SGMO "Held meeting with U.S. Food and Drug Administration (FDA) where, among other things, they reiterated October 2024 agreement to use estimated glomerular filtration rate (eGFR) slope as an endpoint to support accelerated approval pathway for isaralgagene civaparvovec in
1
1
20
$SGMO lol - that’s what it feels like
$SGMO less than 48h What’s the sentiment ?
1
0
13
Interesting contrast to this one, which is rather 50:50 https://t.co/tDlwGttz59
$SGMO less than 48h What’s the sentiment ?
0
0
0
$SGMO — haven’t seen this much optimism here since… ever? 😂🤓
$SGMO which stock price by end of week after tomorrow's call?
5
0
18
@BiotechAnalysst Let’s see if they $SGMO address the cash runway and capital strategy - that’s the only real bottleneck here.
1
2
14
$SGMO Wild week for biotech — the whole sector’s getting smacked and the FDA’s handing out knockout punches like it’s serving Wildberry Lillet. $QURE $SRPT $NTLA $BHVN — all taking hits. Meanwhile, good ol’ $SGMO is just chilling in the mud, happily unbothered as always.
2
0
19
This start to the week makes me all the more curious about the $SGMO ER. Is $SGMO gonna be the joker at the end?! 👀🤓
3
2
24
#FDA maybe that has been the plan from the beginning, but the agency is in total self-destruct mode. Soon there will be a drug approval system based on showing minimal safety. The real fight for the hearts and minds will then take place in the competitive marketplace. Cheaper,
3
1
13